In order to provide useful information for effective control and clinical therapy of infection, the resistance status and the rate of carryingAmpC β-lactamase of Enterobacter cloacae (E. cloacae) were investigated. By VITEK (Bacterial automatic biochemical analyzer), the isolates of E. cloacae were identified and the drug resistance was measured. The AmpC enzyme was detected by the five-disk diffusion test.Antibiotic sensitivity test showed that the resistance effects of E. cloacae to cefazolin, cefoxitin and ampicillin were more serious, with resistant rates of 80.5%, 75.3% and 70.1%, respectively. However, it was more sensitive to Sulperazone (cefoperazone/sulbactam, 13.0%), amikacin (16.9%) and ciprofloxacin (19.5%). Meanwhile, the phenotype detection showed that 35.06% (27/77) isolates of E. cloacae produced AmpC β-lactamase. Most of E. cloacae are multi-drug resistant strains. Sulperazone (cefoperazone/sulbactam), a kind of component β-lactamase, is a more effective antibiotic for treating infection caused by E. cloacae. Unreasonable application of the third generation cephalosporins plays an important role in leading to emergence of high-yield AmpC β-lactamase strains, so antibiotics should be used wisely.
Corresponding Author(s):
LIU Yunde,Email:yundeliu@126.com
引用本文:
. Detection of AmpC β-lactamase and drug resistance of Enterobacter cloacae[J]. Frontiers of Medicine in China, 2009, 3(1): 72-75.
Rong WANG, Shangwei WU, Xue LI, Ping HE, Yunde LIU. Detection of AmpC β-lactamase and drug resistance of Enterobacter cloacae. Front Med Chin, 2009, 3(1): 72-75.
John J F Jr, Sharbaugh R J, Bannister E R. Enterobacter cloacae bacteremia, epidemiology and antibiotic resistance. Rev Infect Dis , 1982, 4(1): 13-28
2
Sanders W E Jr, Sanders C C. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev , 1997, 10(2): 220-241
3
Wisplinghoff H, Bischoff T, Tallent S M, Seifert H, Wenzel R P, Edmond M B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis , 2004, 39(3): 309-317 doi: 10.1086/421946
4
Lamotte-Brasseur J, Knox J, Kelly J A, Charlier P, Fonzé E, Dideberg O, Frére J M. The structure and catalytic mechanisms of active-site serine beta-lactamases. Biotechnol Genet Eng Rev , 1994, 12: 189-230
5
Zhou Z H, Li L J, Yu Y S. Compare two methods of detection AmpC of Enterobacter cloacae. Zhonghua Jianyan Yixue Zazhi , 2002, 25(2): 88-90 (in Chinese)
6
Ying H P, Li M F, Huang Z G. Survey the resistance of Enterobacter cloacae in Nosocomal Infection. Zhejiang Linchuang Yixue , 2004, 5(6): 394 (in Chinese)
7
Shen Q, Shi X Y. 13 drugs resistance analysis of Enterobacter cloacae. Zhejiang Zhongxiyi Jiehe Zazhi , 2002, 8(12): 517 (in Chinese)
8
Cheng Y Q, Song S D, Wei D J, Qi W, Guo W X. Analysis of clinical Distribution and Drug Resistance of Infection due to Enterobacter cloacae. Tianjin Yi Yao , 2003, 5(31): 279-281 (in Chinese)
9
Zhao L, Zhu H Q. The clinical features and drug resistance analysis of 40 cases infected by Enterobacter cloacae. Shanghai Yi Yao , 2000, 3(21): 34-35 (in Chinese)
10
Pitout J D, Thomson K S, Hanson N D, Ehrhardt A F, Coudron P, Sanders C C. Plasmid-mediated resistance to cephalosporins among Enterobacter aerogenes strains. Antimicrob Agents Chemother , 1998, 42(3): 596-600
11
Zhu B, Li X, Wang R, Liu Y D. The Analysis of Resistance to Antimicrobial agents of Enterobacter cloaca. Zhongguo Yixue Jianyan , 2008, 9(5): 267-271 (in Chinese)
12
Gui B D, Wang L. Analysis of multiply resistance of Enterbacter cloacae strains to antimicrobial agents and its molecular epidemiology. Jiangxi Yi Xue Jian Yan , 2004, 22(10): 416-417 (in Chinese)
13
Zhang D S, Yang H T. Drug resistance analysis of 62 Enterbacter cloacae. Yixue Lilun Yu Shijian , 2004, 17(6):697-698 (in Chinese)
14
Zhang L. Survey the prevalence of nosocomial high-yield AmpC of Enterobacter cloaca. Zhonghua Jianyan Yixue Zazhi , 2001, 11(4): 254-257 (in Chinese)
15
Paterson D L, Yu V L. Extended-spectrum beta-lactamases: a call for improved detection and control. Clin Infect Dis , 1999, 29: 1419-1422 doi: 10.1086/313559
16
Lin Q A, Lai G X, Lou W T, Xiu Q Y. On the ESBLs and drug resistance analysis of 55 Enterobacter cloacae. Shanghai Yixue Jianyan Zazhi , 2003, 18(3): 159-160 (in Chinese)
17
Liu D, Zhu X N, Xiao H. ESBLs and AmpC enzyme carriage rates and antimicrobial resistance of 113 strains of Enterobacter cloacae. Zhongguo Ganran Kongzhi Zazhi , 2004, 3(4): 342-344 (in Chinese)
18
Li X L, Huang C W, Ma J. AmpC of the E．cloacae, E．areogenes and Serratiawas detected and its drug resistance was analyzed. Chongqing Yixue , 2003, 32(3): 303-304 (in Chinese)
19
Zhou Z H, Li L J, Yu Y S, Ma Y L. The status of drug resistance and ampC gene expression in Enterobacter cloacae. Chinese Medical Journal , 2003,116(8): 1244-1247
20
Zheng Q , Kang G M , Guo X J , Chen H L, Yan K N, Jian J. In vitro activity of cefmetazole against extended-spectrum beta-lactamases producing and non-producing strains: a comparison with cefoxitin. Zhongguo Ganran Yu Hualiao Zazhi , 2006, 6(1): 50-52 (in Chinese)
